Literature DB >> 3552106

Single dose antibiotic prophylaxis in high risk patients undergoing transurethral prostatectomy.

G P McEntee, S McPhail, D Mulvin, R W Thomson.   

Abstract

In a randomized controlled clinical trial single dose antibiotic prophylaxis (gentamicin 80 mg IV) was evaluated in 36 patients with indwelling urethral catheters undergoing transurethral prostatic resection. Prophylaxis resulted in a significant reduction in postoperative bacteriuria (P less than 0.01), pyrexia (P less than 0.001), bacteraemia (P less than 0.01) and septicaemia (P less than 0.05). During the same period there was one case of postoperative bacteriuria but no systemic infection in 25 consecutive patients undergoing elective prostatectomy with no local risk factors and in the absence of prophylaxis. A policy of selective antibiotic prophylaxis is justified and in high risk patients with in-dwelling catheters single dose prophylaxis is highly effective.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3552106     DOI: 10.1002/bjs.1800740312

Source DB:  PubMed          Journal:  Br J Surg        ISSN: 0007-1323            Impact factor:   6.939


  3 in total

1.  Assessment of antibiotic prophylaxis prescribing patterns for TURP: A need for Canadian guidelines?

Authors:  Keith A Lawson; Jan K Rudzinski; Ingrid Vicas; Kevin V Carlson
Journal:  Can Urol Assoc J       Date:  2013 Jul-Aug       Impact factor: 1.862

Review 2.  Adverse effects of a single dose of gentamicin in adults: a systematic review.

Authors:  Rachel S Hayward; Jan Harding; Rob Molloy; Lucy Land; Kate Longcroft-Neal; David Moore; Jonathan D C Ross
Journal:  Br J Clin Pharmacol       Date:  2017-11-03       Impact factor: 4.335

3.  Pre-procedural antibiotics for endoscopic urological procedures: Initial experience in individuals with spinal cord injury and asymptomatic bacteriuria.

Authors:  Julio T Chong; Adam P Klausner; Albert Petrossian; Michael D Byrne; Jewel R Moore; Lance L Goetz; David R Gater; B Mayer Grob
Journal:  J Spinal Cord Med       Date:  2014-01-21       Impact factor: 1.985

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.